Neues zu EudraCT
Verpflichtendes Hochladen von Abschlussberichten

Dr. Stefan Strasser
Abteilung Klinische Prüfung, Institut Überwachung, AGES MEA

AGES Gespräch
Wien, 25.11.2014
As of 21 July 2014, it will become mandatory for sponsors to post clinical trial results in the European Clinical trials Database (EudraCT), managed by the European Medicines Agency (EMA).

Since the result-related information is fed into the publicly accessible European Union Clinical Trials Register, summary results of clinical trials will become available to the public as sponsors start to comply with their legal obligations.
Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006

(2012/C 302/03)
Implication for NCA/IEC

• replaces submission to the **NCA** (4.3 CT-1)
• replaces submission to the **IEC** (4.2.1 CT-1) (for published trials)

Publication criteria:

*Result-related information on non-paediatric Phase-I clinical trials is not made public!*

Non-paediatric Phase I trials still have to report to the IEC.
Scope

• trials regulated by Directive 2001/20/EC ("Clinical Trials Directive")
• trials regulated by Regulation EC/1901/2006 ("Paediatric Regulation")

Legal Basis

• Article 11 of Directive 2001/20/EC
• Article 57 of Regulation EC/726/2004
• Article 41 of Regulation EC/1901/2006
EC/ 1901/ 2006 trials

- part of a paediatric investigation plan (PIP)
  (including non-paediatric trials and trials outside the EEA)

or

- falling within Article 45 of EC/1901/2006
  “any paediatric studies already completed, by the date of entry into force, in respect of products authorised in the Community”

or

- falling within Article 46 EC/1901/2006
  “any other marketing authorisation holder-sponsored studies which involve the use in the paediatric population of a medicinal product covered by a marketing authorisation, whether or not they are conducted in compliance with an agreed paediatric investigation plan”
2001/20/EC adult trials

All non-paediatric trials conducted in at least one EEA country, whether or not included in an agreed paediatric investigation plan (PIP).

<table>
<thead>
<tr>
<th>End of trial</th>
<th>Composition of results</th>
<th>Timing of posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>On/ After FoP</td>
<td><strong>Full data set</strong> mandatory, summary attachment(s) optional</td>
<td>12 months after EOT</td>
</tr>
<tr>
<td>&lt; 1 year prior to FoP</td>
<td><strong>Full data set</strong> mandatory, summary attachment(s) optional</td>
<td>12 months after FoP</td>
</tr>
<tr>
<td>≥ 1 year prior to FoP</td>
<td><strong>Full data set or summary or both</strong></td>
<td>24 months after FoP</td>
</tr>
</tbody>
</table>

*Finalisation of programming (FoP) = 21 July 2014*
2001/ 20/ EC paediatric trials

Paediatric trials completed after 26 January 2007, conducted in at least one EEA country and not being marketing authorisation holder-sponsored.

<table>
<thead>
<tr>
<th>End of trial</th>
<th>Composition of results</th>
<th>Timing of posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>On/ After FoP</td>
<td><strong>Full data set</strong> mandatory, summary attachment(s) optional</td>
<td>6 months after EOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>12 months (if justified)</strong></td>
</tr>
<tr>
<td>&lt; 1 year prior to FoP</td>
<td><strong>Full data set</strong> mandatory, summary attachment(s) optional</td>
<td>12 months after FoP</td>
</tr>
<tr>
<td>≥ 1 year prior to FoP</td>
<td><strong>Full data set or summary or both</strong></td>
<td>24 months after FoP</td>
</tr>
</tbody>
</table>

Finalisation of programming (FoP) = 21 July 2014
Mitigating Measures

• „Summary attachment“:
  - a copy, authorised by the copy right-holder, of a medical journal article (as PDF file),
  - the synopsis in accordance with Annex I to the ICH E3 guidance (as PDF file),
  - or any other appropriate document containing the information of that synopsis (as PDF file)

• „Justification of 12 months“
  - the clinical trial does not fall within the scope of Article 46 of the Paediatric Regulation, and
  - it is for objective scientific reasons not possible to submit the result-related information within six months, which has been demonstrated by the submitting party
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor/Company:</th>
<th>Individual Study Table Referring to Part of the dossier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Volume:</td>
</tr>
<tr>
<td>Name of Active Ingredient:</td>
<td>Page:</td>
</tr>
</tbody>
</table>

**Title of Study:**

**Investigators:**

**Study centre(s):**

**Publication (reference):**

<table>
<thead>
<tr>
<th>Studied period (years): (date of first enrolment) (date of last completed)</th>
<th>Phase of development:</th>
</tr>
</thead>
</table>

**Objectives:**

**Methodology:**

**Number of patients (planned and analysed):**

**Diagnosis and main criteria for inclusion:**

**Test product, dose and mode of administration, batch number:**

**Duration of treatment:**

**Reference therapy, dose and mode of administration, batch number:**

---

**ANNEX I cont.**

<table>
<thead>
<tr>
<th>Name of Sponsor/Company:</th>
<th>Individual Study Table Referring to Part of the dossier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Volume:</td>
</tr>
<tr>
<td>Name of Active Ingredient:</td>
<td>Page:</td>
</tr>
</tbody>
</table>

**Criteria for evaluation:**

**Efficacy:**

**Safety:**

**Statistical methods:**

**SUMMARY - CONCLUSIONS**

**Efficacy results:**

**Safety results:**

**Conclusion:**

**Date of the report:**
Paediatric trials completed after 26 January 2007 which involve the use of a medicinal product covered by an EU marketing authorisation and sponsored by the marketing authorisation holder, whether or not included in an agreed PIP.

<table>
<thead>
<tr>
<th>End of trial</th>
<th>Composition of results</th>
<th>Timing of posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>On/ After FoP</td>
<td>Full data set mandatory, summary attachment(s) optional</td>
<td>6 months after EOT</td>
</tr>
<tr>
<td>Prior to FoP</td>
<td>Full data set mandatory, summary attachment(s) optional</td>
<td>12 months after FoP</td>
</tr>
</tbody>
</table>

Finalisation of programming (FoP) = 21 July 2014
Paediatric trials in respect of products covered by an EU marketing authorisation on 26 January 2007, completed by 26 January 2007.

<table>
<thead>
<tr>
<th>End of trial</th>
<th>Composition of results</th>
<th>Timing of posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to 26.01.2007</td>
<td>Summary of study submitted to EMA and uploaded by the Agency for publication</td>
<td>24 months after FoP</td>
</tr>
</tbody>
</table>

*Finalisation of programming (FoP) = 21 July 2014*
Paediatric trials included in an agreed PIP, not sponsored by the marketing authorisation holder and conducted fully outside the EEA.

<table>
<thead>
<tr>
<th>End of trial</th>
<th>Composition of results</th>
<th>Timing of posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>On/ After FoP</td>
<td>Full data set mandatory, summary attachment(s) optional</td>
<td>6 months after EOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 months if justified</td>
</tr>
<tr>
<td>Prior to FoP</td>
<td>Full data set mandatory, summary attachment(s) optional</td>
<td>12 months after FoP</td>
</tr>
</tbody>
</table>

*Finalisation of programming (FoP) = 21 July 2014*
Reporting modalities

• If the clinical trial ends **prematurely**, that date should be considered the end of the trial.

• Only one set of result-related data may be provided per planned analysis and trial. **If the outcome is analysed on several occasions, each of these analyses should be posted.**

• Information should be posted in **English**. In addition, the information may be posted in any other official EU language.
The posted result-related information is made public through the EU Clinical Trials Register (only result-related information on non-paediatric Phase-I clinical trials is not made public.)

The result-related information is made public within 15 working days from the posting of a valid data set.

In addition to being readable in situ on the web, the data will also be made available in a printable format and in a downloadable format.

The web interface is going to provide tools to facilitate the searching, reading and browsing of the public information on clinical trials and their results.
Non-compliance & factual inaccuracy

• **Member States should verify** that for clinical trials authorised by them the result-related information is posted to the Agency.

• Clinical trials for which no result-related information has been posted 9 months after the end of the trial for paediatric trials or 15 months for other trials will be flagged.

• This information will be **publicly available**. The anticipated duration of the trial is entered at the time of the clinical trial application.

• All corrections to published information will be made by the **party posting that information**, sometimes upon request by the Agency.
GCP Inspections

- If inspections of compliance with good clinical practice (GCP) reveal that there are serious doubts about the accuracy or reliability of the result-related data, the Agency will be informed immediately.

- The Agency will retain the possibility of:
  - **removing** information from the public view,
  - **highlighting** that the result-related information may not be valid in view of GCP non-compliance, or
  - **adding a notice to the public record**, where necessary for reasons of factual accuracy or compliance with regulatory requirements.
Full-Data-Set Contents

**Trial information**
- Study identification
- Identifiers
- Sponsor details
- Paediatric regulatory details
- Result analysis stage
- General Information about the trial
- Population of trial subjects with actual number of subjects included in the trial

**End Points**
- Endpoint definitions
  - End Point #1
    --- Statistical Analyses
  - End Point #2
    --- Statistical Analyses
  ...

**Subject disposition**
- Recruitment
- Pre-assignment Period
- Post-Assignment Periods

**Adverse Events**
- Adverse events information
- Adverse event reporting group
- Serious Adverse Events
- Non-serious adverse event

**Baseline Characteristics**
- Age
- Gender
- Study Specific

**More Information**
- Global Substantial Amendments
- Global Interruptions and re-starts
- Limitations & Caveats
Trial Information Form

• **General Information**
  - Result analysis stage
  - Protection of subjects
  - Background therapy
  - Evidence for comparators

• **Number of subjects included**
  - Actual number per country
  - Actual age breakdown
Subject Disposition Form

- **Subject disposition – Pre-Assignment**
  - Recruitment & screening details
  - Milestones & status of completion

- **Subject disposition – Baseline**
  - Allocation & blinding details
  - Description of arms
  - Milestones & status of completion

- **Products used**
  - Use of EudraCT data?
  - Dosage and administration details

- **Subject analysis**
  - Analysis set description
  - Number of subjects
Subject Disposition (Example)

DISPOSITION OF PATIENTS

N = 1,724
PATIENTS RECEIVING DOUBLE-BLIND MEDICATION

N = 340
REGIMEN A

N = 281
COMPLETED STUDY

ADVERSE EVENT (20)
UNSAT. RESPONSE (2)
EFFICACY (1)
FAILURE TO RETURN (6)
OTHER MED. EVENT (3)
OTHER NONMED. EVENT (5)
PROTOCOL VIOLATION (10)
PATIENT REQUEST (12)

N = 59
WITHDRAWN

N = 340
REGIMEN B

N = 281
COMPLETED STUDY

ADVERSE EVENT (19)
UNSAT. RESPONSE (2)
EFFICACY (1)
FAILURE TO RETURN (8)
OTHER MED. EVENT (8)
OTHER NONMED. EVENT (4)
PROTOCOL VIOLATION (10)
PATIENT REQUEST (10)

N = 59
WITHDRAWN

N = 340
REGIMEN C

N = 261
COMPLETED STUDY

ADVERSE EVENT (26)
UNSAT. RESPONSE (1)
EFFICACY (1)
FAILURE TO RETURN (7)
OTHER MED. EVENT (4)
OTHER NONMED. EVENT (6)
PROTOCOL VIOLATION (3)
PATIENT REQUEST (25)

N = 79
WITHDRAWN

N = 340
REGIMEN D

N = 246
COMPLETED STUDY

ADVERSE EVENT (24)
UNSAT. RESPONSE (1)
EFFICACY (1)
FAILURE TO RETURN (6)
OTHER MED. EVENT (8)
OTHER NONMED. EVENT (7)
PROTOCOL VIOLATION (6)
PATIENT REQUEST (27)

N = 94
WITHDRAWN

N = 340
REGIMEN E

N = 242
COMPLETED STUDY

ADVERSE EVENT (42)
UNSAT. RESPONSE (0)
EFFICACY (0)
FAILURE TO RETURN (6)
OTHER MED. EVENT (14)
OTHER NONMED. EVENT (1)
PROTOCOL VIOLATION (14)
PATIENT REQUEST (15)

N = 98
WITHDRAWN

N = 1,361
PATIENTS COMPLETING STUDY

ICH E3 Structure and Content of Clinical Study Reports
Baseline Characteristics Form

• **Age**
  - Per reporting group
  - Continuous

• **Gender**
  - Per reporting group

• **Study specific - mandatory or optional?**
  - Per reporting group
  - Continuous values (if applicable)
Endpoints Form

- Type (primary, secondary, exploratory, post-hoc)
- Title & description
- Time frame
- Analysis set
- Per reporting group
- Statistical analysis description

For each endpoint!
Adverse Event Form

• General
  - Time frame & dictionary
  - Method & threshold for no serious events

• Serious adverse events & non-serious adverse events
  - system organ class, term, description
  - number exposed/affected
  - outcomes

• Fatalities
More Information

- Amendments
- Global Interruptions and Restarts
- Limitations and Caveats
Information Initiatives

• FAQs and Guidance Documents

• Stakeholder Presentations

• Informal E-Mail Reminder to all sponsors of trials in Austria

• Scenarios for non-commercial sponsors (together with academia)

• Further steps in development…
EMA launches EudraCT result training environment

The EMA launched the EudraCT result training environment 1 August 2014. This application is aimed at representatives of sponsors and sponsor-investigators who want to familiarise themselves and get a better understanding in the preparation and posting of trials results in EudraCT. Further information can be found on the EudraCT result training environment home page.

Result related documentation

- Trial results modalities and timing of posting
- Clinical trial assignment request template letter
- EudraCT result related data dictionary
- Validation rules for posting result related information
- XML schemas and documentation
- Service level agreement

Training on EudraCT results

- Getting started with EudraCT to prepare and post results
- Managing users and preparing results in EudraCT
- Questions from the V9 workshop - 30 October 2013
- Questions from the V9 workshop - 15 November 2013
- Questions from the V9 workshop - 20 November 2013
- EudraCT V10 - Q&A for 19 Sept 2014 session
- Training session for Stakeholders CT results EudraCT V10
Thank you for your attention!

Questions?